Overview

Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis

Status:
Terminated

Trial end date:
2018-11-14

Target enrollment:

Participant gender:

Summary

The humanised IgG4 monoclonal antibody GNbAC1 targets the envelope protein (Env) of the human endogenous multiple sclerosis-associated retrovirus (HERV-W MSRV), which may play a critical role in multiple sclerosis. The study assesses the long-term safety of GNbAC1 in patients with RRMS and the long-term efficacy of GNbAC1 in terms of MRI outcomes, relapse rate, disability and disease progression.

Phase:

Phase 2

Details

Lead Sponsor:

GeNeuro SA

Collaborators:

Institut de Recherches Internationales Servier
Les Laboratoires Servier
Worldwide Clinical Trials

Treatments:

Antibodies
Antibodies, Monoclonal
Immunoglobulins